Clinical Bioequivalence of Wixela Inhub and Advair Diskus in Adults With Asthma

摘要

Wixela Inhub is a dry powder inhaler approved as a generic equivalent to Advair Diskus (fluticasone propionate [FP]/salmeterol fixed-dose combination) for patients with asthma or chronic obstructive pulmonary disease (COPD). This study aimed at confirming the local (lung) therapeutic equivalence of both the FP and salmeterol components of Wixela Inhub (test [T]) to Advair Diskus (reference [R]) after inhalation.